iCrowd Newswire
19 May 2022, 23:02 GMT+10
The latest study from BIS Research on the acellular therapy market suggests a substantial increase in the adoption of cell-free therapy across different medical disciplines, such as oncology, neurology, and cardiology.
The premium market intelligence by BIS Research also highlights the opportunities existing in the market, including the high scope for adoption of the acellular therapy approach in emerging nations and providing a solution for the treatment of infectious diseases, oncology (solid tumor, breast cancer, pancreatic cancer, and metastatic colorectal cancer), skin disorders, and neurological disorders.
The study also offers strategic recommendations that can help organizations track various products, trends, and applications that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.
The detailed study is a compilation of 54 Figures spread through 85 Pages and in-depth TOC on "Global Acellular Therapy Market – Strategies and Applications"
USP of the Report
This extensive report can help in the following ways:
Analyst's Take on the Market:
According to Nitish Kumar Singh, Principal Analyst – BIS Research, "Acellular therapy holds immense potential to restructure the healthcare industry. It is an emerging approach that enables the investigation of multiple diseases such as infectious diseases, oncology (solid tumor, breast cancer, pancreatic cancer, and metastatic colorectal cancer), skin disorders, and neurological disorders by evaluating cell-free or exosome-based treatment, thereby providing tailored therapeutic treatment to each patient."
View the report from BIS Research on Global Acellular Therapy Market
Key Companies Operating in the Market and Competition Landscape
Key insights are drawn from in-depth interviews with the key opinion leaders of the leading companies, market participants, and vendors. The key players profiled in the report include Aegle Therapeutics Corp, Aruna Biomedical, Capricor Therapeutics, Inc., Codiak BioSciences, Inc., Direct Biologics, LLC, EV Therapeutics, Inc., Evox Therapeutics Ltd, Exogenus Therapeutics, Invitrx Therapeutics, Inc., Organicell Regenerative Medicine, Inc., Rion LLC, and Stem Cell Medicine Ltd.
Who Should Buy This Report?
Key Questions Answered in the Report:
BIS Research Related Market Studies:
Global Regenerative Medicines Market
About BIS Research:
BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends which can disrupt the market dynamics in the near future. We publish more than 200 market intelligence studies annually that focus on several deep technology verticals.
Our strategic market analysis emphasizes on market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.
BIS Research offers syndicate as well as custom studies and expert consultations to firms, providing them specific and actionable insights on novel technology markets, business models, and competitive landscape.
BIS Healthcare vertical offers intelligence in the healthcare technology market for Medical Devices, Digital Health, Life Sciences, Robotics and Imaging, Information Technology, Precision Medicine, and other emerging healthcare technologies, covering the entire industry spectrum. In the past 5 years, BIS Healthcare has published more than 50 reports under the precision medicine banner. Additionally, BIS Research has been nominating Top 25 Voices in Precision Medicine on its Insight Monk platform for the past two years successfully.
Contact:
Head of Marketing
Email: media@bisresearch.com
BIS Research Inc.
39111 PASEO PADRE PKWY STE 313,
FREMONT CA 94538-1686
Visit our Blog @ https://bisresearch.com/news
Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research
Connect with us on Twitter@ https://twitter.com/BISResearch
Tags: Oncology, technology, Healthcare, Neurology, Cardiology, MedTech, medical science, acellular therapy
See Campaign: https://bit.ly/3ws2huf
media@bisresearch.com
Tags:Reportedtimes, Financial Content, PR-Wirein, Extended Distribution, iCN Internal Distribution, Research Newswire, EnglishGet a daily dose of Texas Guardian news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Texas Guardian.
More InformationByron Buxton strives to follow up a strong outing when the Minnesota Twins visit the Cleveland Guardians in Monday's opener ...
After wasting a 4-0 lead in their 6-5 10-inning loss to the Chicago Cubs Sunday to lose their weekend series, ...
The surging Boston Red Sox will try to extend their seven-game winning streak on Monday night when they visit the ...
The New York Yankees spent a long weekend against the Houston Astros never holding a lead until Aaron Judge's bat ...
The Colorado Avalanche defeated the Tampa Bay Lightning 2-1 Sunday night to win the National Hockey League's Stanley Cup.The Avalanche ...
David MacKinnon's two-out RBI single in the seventh inning snapped a 1-1 tie and lifted the Los Angeles Angels to ...
SYDNEY, NSW, Australia - Stocks across Asia rose on Monday, in a positive start to the week.The U.S. dollar was ...
TOKYO, Japan: Amidst semiconductor shortages and COVID-19 parts supply disruptions, Toyota has reduced its July global production target by 50,000 ...
NEW YORK CITY, New York: Electric vehicle (EV) sales could reach 33 percent globally by 2028, and 54 percent by ...
BERLIN, Germany: To prevent large increases in food prices, officials from G7 countries, including Germany and the UK, will push ...
WASHINGTON D.C.: The U.S. Food and Drug Administration (FDA) is preparing to order Juul Labs to stop selling its e-cigarettes ...
WASHINGTON D.C.: As average home prices surged to a record high, reaching the $400,000 mark for the first time, and ...